Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Moodys
AstraZeneca
Medtronic
Mallinckrodt
McKesson
Baxter

Last Updated: November 18, 2019

DrugPatentWatch Database Preview

LYMPHOSEEK KIT Drug Profile

See Plans and Pricing

« Back to Dashboard

Which patents cover Lymphoseek Kit, and when can generic versions of Lymphoseek Kit launch?

Lymphoseek Kit is a drug marketed by Cardinal Health 414 and is included in one NDA. There are two patents protecting this drug.

This drug has twenty-six patent family members in twelve countries.

The generic ingredient in LYMPHOSEEK KIT is technetium tc-99m tilmanocept. There are four drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the technetium tc-99m tilmanocept profile page.

Summary for LYMPHOSEEK KIT
International Patents:26
US Patents:2
Applicants:1
NDAs:1
Suppliers / Packagers: 1
Clinical Trials: 19
DailyMed Link:LYMPHOSEEK KIT at DailyMed
Drug patent expirations by year for LYMPHOSEEK KIT
Generic Entry Opportunity Date for LYMPHOSEEK KIT
Generic Entry Date for LYMPHOSEEK KIT*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
INJECTABLE;INJECTION

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for LYMPHOSEEK KIT

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Washington University School of MedicinePhase 1
National Cancer Institute (NCI)Phase 2
Eben RosenthalPhase 2

See all LYMPHOSEEK KIT clinical trials

US Patents and Regulatory Information for LYMPHOSEEK KIT

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Cardinal Health 414 LYMPHOSEEK KIT technetium tc-99m tilmanocept INJECTABLE;INJECTION 202207-001 Mar 13, 2013 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Cardinal Health 414 LYMPHOSEEK KIT technetium tc-99m tilmanocept INJECTABLE;INJECTION 202207-001 Mar 13, 2013 RX Yes Yes   Start Trial   Start Trial Y Y   Start Trial
Cardinal Health 414 LYMPHOSEEK KIT technetium tc-99m tilmanocept INJECTABLE;INJECTION 202207-001 Mar 13, 2013 RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for LYMPHOSEEK KIT

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1178838 15C0033 France   Start Trial PRODUCT NAME: TILMANOCEPT; REGISTRATION NO/DATE: EU/1/14/955 20141121
1178838 300736 Netherlands   Start Trial PRODUCT NAME: TILMANOCEPT, DESGEWENST GELABELD MET TECHNETIUM TC 99M; REGISTRATION NO/DATE: EU/1/14/955 20141119
1178838 122015000033 Germany   Start Trial PRODUCT NAME: TILMANOCEPT; REGISTRATION NO/DATE: C(2014) 8901 FINAL 20141119
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Boehringer Ingelheim
Dow
Baxter
Moodys
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.